See feature article below: (NASDAQ: PULM)
Broad Street Alerts recent profiles and track record, 433% in verifiable potential gains for our members on the last 2 small cap alerts alone!
May 11th, 2016- (NASDAQ: STEM) opened $2.92/share hit a high of $3.90/share within a few hours our member potential gains- 33%
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit 3.26/share within one week for gains of 400% for our members.
Report for: Pulmatrix, Inc. (NASDAQ: PULM)
Shares of PULM are up today as the company released its Q1 financials. The good news from the financial report is that PULM has sufficient cash on hand to finance the further development is its drug pipeline well into 2017. The report below give a good description of the company’s drug platform and current projects.
LEXINGTON, Mass., April 19, 2016 /PRNewswire/ — Pulmatrix, Inc. (PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight infections.
As Dr. Hava explains, bacterial, viral, and fungal lung infections “afflict millions of people annually.”
Particularly at risk are patients whose immune systems or lungs are compromised. In people with cystic fibrosis (CF), for instance, mucus accumulates in the airways. As a result, “patients with CF become colonized with a number of different bacteria early in life and eventually become chronically colonized with pathogens,” Dr. Hava writes. In addition, many cystic fibrosis patients become infected with a spore-forming mold called Aspergillus fumigatus, which often then causes an allergic reaction.
To fight these infections, companies have developed innovative new strategies for delivering antibiotics and antifungal drugs directly to the lungs, Dr. Hava writes.
For instance, companies have created liquid solutions of antibiotics that are turned into a fine mist using a device called a jet nebulizer. The mist then can be inhaled into the lungs.
As Dr. Hava describes, Novartis AG has developed an inhaled version of the antibiotic tobramycin, while Gilead has a product with a second antibiotic, aztreonam. Other drugs are in clinical trials.
These inhaled drugs represent a major step forward, Dr. Hava writes: “The development of nebulized inhaled antibiotics provided a major advance to address significant unmet need in CF.”
But there are limitations to delivering drugs to the lungs with nebulizers, Dr. Hava explains. That’s why scientists and companies, such as Novartis, Acorda Therapeutics, and Savara, are developing formulations using dry powders that can be inhaled.
In one promising new strategy, Pulmatrix is creating small, dense drug particles that can be easily inhaled using its patented particle engineering technology, iSPERSE.
Pulmatrix is now developing an inhaled product using an antifungal drug, itraconazole, for cystic fibrosis patients. Recent studies show that oral itraconazole is effective in treating CF patients who are suffering from allergic bronchopulmonary aspergillosis (ABPA). The problem, though, is that high oral doses are needed to get enough of the antifungal drug to the lungs through the bloodstream. That causes severe side effects that must be managed and monitored—including liver toxicity.
Delivering the drug directly to the lungs can dramatically reduce the risks of both side effects and drug-drug interactions, Dr. Hava believes. Such an approach offers benefits not just to cystic fibrosis patients but also to many others with compromised immure systems and fungal lung infections.
The Pulmatrix drug candidate, called PUR1900, “has the potential to provide a valuable addition to current treatment options for pulmonary fungal diseases,” Dr. Hava concludes.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix’s product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Source – Company Press Release
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news